Parkinson's Disease Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 40 to 75 years who have been diagnosed with Parkinson's disease (using a standard set of diagnostic criteria called the UK Brain Bank criteria) within the past three years.
- People who have been on a stable, optimised Parkinson's medication plan — using dopamine agonists, levodopa, MAOB inhibitors, or a combination — for at least one month before the trial starts, and who are expected to continue that same plan for at least six months.
- People who are willing and able to sign a consent form agreeing to take part in the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who score 3 or higher on the Hoehn and Yahr scale (a 1–5 scale measuring Parkinson's severity), which indicates at least moderate disease affecting both sides of the body with some balance problems.
- People who experience fluctuations in their movement control or other motor complications related to their Parkinson's treatment.
- People who have a severe psychiatric condition — such as severe anxiety, depression, or schizophrenia — that cannot be adequately managed with medication.
- People whose Parkinson's symptoms are caused by something other than typical Parkinson's disease (known as atypical or secondary Parkinsonism).
- People who score 18 or below on the Montreal Cognitive Assessment (MoCA), a memory and thinking test scored out of 30, which at that level suggests at least mild cognitive impairment.
- People who have Type 1 or Type 2 diabetes, or who have previously been treated with a class of diabetes medications called DPP-4 inhibitors or GLP-1 receptor agonists.
- People with severely reduced kidney function, active liver disease, a history of drug or alcohol misuse, inflammation of the pancreas (either a single episode or ongoing), or who have had part or all of their pancreas surgically removed.
- People whose body weight falls into the underweight range (a BMI below 18.5), or who have lost or gained more than 5 kilograms in the three months before the screening visit.
- People who are currently taking part in another clinical trial involving a medication or surgical treatment.
- People whom the trial investigators believe would be unable to fully participate in or complete all the assessments required by the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
The change in the third part of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) after 12 months of oral Vildagliptin treatment compared to baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.